(2) During treatment with the other two drugs, anti-CTLA-4 and anti-MUC1, smokers are more likely to respond better than the non-smokers in the treatment of NSCLC patients (Supplementary Material, Part D, Part I). This evidence concerns the gene MUC1 and non-small cell lung carcinoma.